Research company Peptonic Medical has acquired 2.78 million shares in DGH International, corresponding to approximately 8.3 percent of the capital and votes. The purchase price is SEK 12.5 million, of which SEK 2.4 million is paid in cash, SEK 9 million is financed through loans from the sellers and SEK 1.1 million through deferred payment. The seller loans may later be requested to be offset against shares in Peptonic. The board sees attractive risk-adjusted potential despite, among other things, ongoing disputes in DGH.